InMed Pharmaceuticals Inc (INM)

[frozenspokes]

Last week's patent talk got me intrigued, so i dug around this weekend. I can't find any patents for IMLFF. Funny that someone mentioned NMUS last week b/c in my research, I did find Cannabinoid Glaucoma patents for them both in the USA and internationally for their drug. They have other patents also and just released the announcement below this morning (timely). I'm going to dig into Nemus as well - looks like a gem that hasn't been discovered yet & they're starting trials soon. Will check out their board and post more over there if applicable. Hope someone can help on the IMLFF patents in the mean time.

https://finance.yahoo.com/news/nemus-bioscience-signs-development-agreement-123000654.html

NEMUS Bioscience, Inc. ( OTCQB : NMUS ) announced that the company has signed a development agreement with Nanomerics Ltd. of the United Kingdom, to develop a topical ocular formulation of tetrahydrocannabinol-valine-hemisuccinate (THCVHS), the prodrug of THC, which is the active component of Nemus drug candidate NB1111 being developed for the treatment of glaucoma. The aim of the agreement is to conduct initial studies assessing the preparation of clinical-grade eye drops using the patented Molecular Envelope Technology (MET) developed by Nanomerics. Work under the agreement will commence on a future date to be determined by Nemus in connection with its development plans and corporate objectives.

"Nanomerics looks forward to working with Nemus on creating medicines that address the medical need for the improved treatment of glaucoma. Nemus, as the only cannabinoid company we are aware of with a complement of prodrugs and analogues of THC and CBD, is uniquely placed to potentially develop these for use in multiple forms of ocular disease," commented Professor Andreas Schätzlein, co-founder and CEO of Nanomerics. Nanomerics' CSO and co-founder Professor Ijeoma Uchegbu explained, "We feel that the MET platform will help NB1111 deliver in the clinic what has already been shown in several animal studies. Namely, penetration into multiple chambers of the eye, a non-opaque eye drop, and a neutral-pH at delivery to lower the risk of eye irritation which is an adverse event seen with some established therapies in glaucoma."